Anti-TNF agents for the treatment of psoriasis

Keyphrases

• Psoriasis Treatment 100%
• Psoriasis 100%
• Anti-TNF Agents 100%
• Combination Therapy 28%
• Biological Agents 28%
• Phototherapy 28%
• Quality of Life 14%
• National Institutes of Health 14%
• Clinical Trials 14%
• Malignancy 14%
• Congestive Heart Failure 14%
• Severe Disease 14%
• Multisystem 14%
• Pharmacologic 14%
• Treatment Strategy 14%
• Systemic Therapy 14%
• Clinical Data 14%
• Plaque Psoriasis 14%
• Cyclosporine 14%
• Demyelinating Diseases 14%
• Moderate to Severe 14%
• Safety Considerations 14%
• Clinical Practice 14%
• Tolerability 14%
• Monotherapy 14%
• Armamentarium 14%
• Overall Health 14%
• Safety Data 14%
• Mild Disease 14%
• Response Rate 14%
• Anti-tumor Necrosis Factor (anti-TNF) 14%
• Psoriatic Arthritis 14%
• Infliximab 14%
• Systemic Disease 14%
• Pathophysiologic 14%
• Immune Mediators 14%
• Symptom Relief 14%
• Adalimumab 14%
• Lack of Response 14%
• Etanercept 14%
• Traditional Agents 14%
• Topical Treatment 14%
• FDA-approved Drugs 14%
• Adverse Events Profile 14%
• Immunological Mechanisms 14%
• Total Annual Cost 14%
• Data Interpretation 14%
• Topical Agents 14%
• Cytopenia 14%
• TNF-α Antagonists 14%
• Acitretin 14%
• Cutaneous Symptoms 14%
• Lupus-like Syndrome 14%
• Targeted Phototherapy 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Psoriasis 100%
• Tumor Necrosis Factor Inhibitor 100%
• Diseases 55%
• Tumor Necrosis Factor 22%
• Combination Therapy 22%
• Adverse Event 11%
• Monotherapy 11%
• Congestive Heart Failure 11%
• Clinical Trial 11%
• Infection 11%
• Psoriasis Vulgaris 11%
• Tolerability 11%
• Infliximab 11%
• Adalimumab 11%
• Ciclosporin 11%
• Etanercept 11%
• Topical Agent 11%
• Etretin 11%
• Systemic Disease 11%
• Cytopenia 11%
• Demyelinating Disease 11%
• Lupus Like Syndrome 11%